Literature DB >> 22130895

BiNGS!SL-seq: a bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen.

Jihye Kim1, Aik Choon Tan.   

Abstract

While targeted therapies have shown clinical promise, these therapies are rarely curative for advanced cancers. The discovery of pathways for drug compounds can help to reveal novel therapeutic targets as rational combination therapy in cancer treatment. With a genome-wide shRNA screen using high-throughput genomic sequencing technology, we have identified gene products whose inhibition synergizes with their target drug to eliminate lung cancer cells. In this chapter, we described BiNGS!SL-seq, an efficient bioinformatics workflow to manage, analyze, and interpret the massive synthetic lethal screen data for finding statistically significant gene products. With our pipeline, we identified a number of druggable gene products and potential pathways for the screen in an example of lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22130895     DOI: 10.1007/978-1-61779-400-1_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

1.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Authors:  Courtney L Jones; Christy M Gearheart; Susan Fosmire; Cristina Delgado-Martin; Nikki A Evensen; Karen Bride; Angela J Waanders; Faye Pais; Jinhua Wang; Teena Bhatla; Danielle S Bitterman; Simone R de Rijk; Wallace Bourgeois; Smita Dandekar; Eugene Park; Tamara M Burleson; Pillai Pallavi Madhusoodhan; David T Teachey; Elizabeth A Raetz; Michelle L Hermiston; Markus Müschen; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Michael J Garabedian; Christopher C Porter; William L Carroll
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113

2.  RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis.

Authors:  Tohru Yonekawa; Graciela Gamez; Jihye Kim; Aik Choon Tan; Jackie Thorburn; Jacob Gump; Andrew Thorburn; Michael J Morgan
Journal:  EMBO Rep       Date:  2015-04-23       Impact factor: 8.807

3.  A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.

Authors:  Lina Y Dimberg; Christina G Towers; Kian Behbakht; Taylor J Hotz; Jihye Kim; Susan Fosmire; Christopher C Porter; Aik-Choon Tan; Andrew Thorburn; Heide L Ford
Journal:  Mol Cancer Res       Date:  2017-01-20       Impact factor: 5.852

4.  Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

Authors:  Matias Casás-Selves; Jihye Kim; Zhiyong Zhang; Barbara A Helfrich; Dexiang Gao; Christopher C Porter; Hannah A Scarborough; Paul A Bunn; Daniel C Chan; Aik Choon Tan; James DeGregori
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

5.  ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.

Authors:  Mark A Gregory; Angelo D'Alessandro; Francesca Alvarez-Calderon; Jihye Kim; Travis Nemkov; Biniam Adane; Andrii I Rozhok; Amit Kumar; Vijay Kumar; Daniel A Pollyea; Michael F Wempe; Craig T Jordan; Natalie J Serkova; Aik Choon Tan; Kirk C Hansen; James DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

6.  Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.

Authors:  Guolin Zhang; Hannah Scarborough; Jihye Kim; Andrii I Rozhok; Yian Ann Chen; Xiaohui Zhang; Lanxi Song; Yun Bai; Bin Fang; Richard Z Liu; John Koomen; Aik Choon Tan; James Degregori; Eric B Haura
Journal:  Sci Signal       Date:  2016-10-18       Impact factor: 8.192

7.  Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

Authors:  Katherine R Singleton; Trista K Hinz; Emily K Kleczko; Lindsay A Marek; Jeff Kwak; Taylor Harp; Jihye Kim; Aik Choon Tan; Lynn E Heasley
Journal:  Cancer Res       Date:  2015-09-10       Impact factor: 12.701

8.  Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Authors:  Jihye Kim; Vihas T Vasu; Rangnath Mishra; Katherine R Singleton; Minjae Yoo; Sonia M Leach; Eveline Farias-Hesson; Robert J Mason; Jaewoo Kang; Preveen Ramamoorthy; Jeffrey A Kern; Lynn E Heasley; James H Finigan; Aik Choon Tan
Journal:  Bioinformatics       Date:  2014-05-07       Impact factor: 6.937

9.  A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines.

Authors:  Katherine R Singleton; Jihye Kim; Trista K Hinz; Lindsay A Marek; Matias Casás-Selves; Clark Hatheway; Aik Choon Tan; James DeGregori; Lynn E Heasley
Journal:  Mol Pharmacol       Date:  2013-01-31       Impact factor: 4.436

10.  A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation.

Authors:  Zdenek Andrysik; Jihye Kim; Aik Choon Tan; Joaquín M Espinosa
Journal:  Cell Rep       Date:  2013-05-16       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.